CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

On January 29, 2025 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET (Press release, CRISPR Therapeutics, JAN 29, 2025, View Source [SID1234649921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

On January 29, 2025 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, reported that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Press release, AN2 Therapeutics, JAN 29, 2025, View Source [SID1234649920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follows:

Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)

Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer

On January 29, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that clinical data for its 4-1BB agonist, ATOR-1017, has been published in the Journal for ImmunoTherapy of Cancer (JITC) (Press release, Alligator Bioscience, JAN 29, 2025, View Source [SID1234649919]). This publication validates ATOR-1017’s safety and tolerability in patients with advanced cancers and highlights early signs of clinical efficacy. Additionally, pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism, further supporting the therapeutic potential of ATOR-1017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This publication adds to previously published preclinical data and underscores the scientific foundation of ATOR-1017 as an immunotherapy designed to activate T cells and natural killer (NK) cells in a tumor-specific manner. These findings strengthen the clinical package for ATOR-1017 and support its potential for future development, particularly in combination with other anticancer agents.

Dr. Sumeet Ambarkhane, Chief Medical Officer of Alligator Bioscience, commented:
"These first-in-human clinical data of ATOR-1017 in the Journal for ImmunoTherapy of Cancer demonstrate excellent safety profile and biological activity ATOR-1017. This peer-reviewed publication also reaffirms the scientific value of targeting 4-1BB pathway as a cancer immunotherapy, and further enhances its potential for future development."
Alligator remains focused on advancing its lead candidate, mitazalimab, while exploring strategic opportunities to realize the potential of ATOR-1017.

Imugene receives A$20 million for convertible notes issue

On January 29, 2025 Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, reported that it has received A$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, Inc (Press release, Imugene, JAN 29, 2025, https://mcusercontent.com/e38c43331936a9627acb6427c/files/e589213b-3647-e75b-54a9-d992df0585cc/Imugene_Receives_A_20_million_for_Convertible_Notes_Issuance.pdf [SID1234649910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This funding represents the first tranche of a total A$46 million capital raising announced on 23 December 2024, comprising convertible notes and associated unlisted warrants. The proceeds from this initial tranche will be directed toward advancing Imugene’s immuno-oncology clinical trial pipeline, including azer-cel, onCARlytics, and VAXINIA programs.

The convertible notes, with a five-year maturity, provide significant flexibility for Imugene, with no interest costs and potential semi-annual conversion to ordinary shares at a premium to the Company’s market price.

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

On January 28, 2025 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that management will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025 at The Cliff Lodge in Snowbird, UT (Press release, Delcath Systems, JAN 28, 2025, View Source [SID1234649922]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!